-
Dispersed Phase Formulations: What it Takes to Take It From Bench Scale to Clinical to Commercialization Scale
Tuesday, November 13
2:00 pm – 4:00 pm
Roundtable
ACPE #073-999-07-560-L04
There is a significant increase in the use of dispersed phase formulations to formulate small molecules, proteins, peptides and other biologics to solubilize, stabilize, or to increase half-life and improve other attributes leading to clinical benefits to patients. The objective of this session is to educate the attendee about what it takes to take a dispersed phase formulation once developed at bench scale to commercialization.
Moderators
Atul Khare, Ph.D.
Baxter Healthcare Corporation
Scott Akers
Baxter Pharmaceutical Solutions LLC
The Development of Disperse-phase Products in a Big Pharma Environment
Clive Washington, Ph.D.
AstraZeneca
Process Development and Scale-Up of Dispersed Phase Formulations
Mark Doty, Ph.D.
Baxter Healthcare Corporation
Technology Transfer Considerations from non-GMP to GMP: Process Considerations and Pitfalls to Avoid
Gavin Sy, M.S.
Pfizer Inc.